Literature DB >> 7077747

Effect of glycosylation inhibitors on the release of enveloped vaccinia virus.

L G Payne, K Kristensson.   

Abstract

Addition of 1 to 10 mM 2-deoxy-D-glucose (2-dg) or glucosamine (gln) to the growth medium of vaccinia virus-infected cells inhibited the release of extracellular enveloped vaccinia virus (EEV) without affecting the production of intracellular naked vaccinia virus (INV) particles. In contrast, INV infectivity (particles per PFU) was decreased sevenfold by 50 mM 2-dg. Treatment with 2-dg reduced but did not eliminate glycosylation of the INV 37,000-molecular-weight glycoprotein. The kinetics of sensitivity to inhibitor addition experiments and inhibitor reversal experiments indicated that EEV release was dependent on glycosylation before 8 h postinfection. This was supported by polyacrylamide gel electrophoretic analysis of the synthesis kinetics for cell membrane-associated vaccinia glycoproteins in 2-dg-inhibited infected cells. The dependence of vaccinia protein glycosylation before 8 h postinfection for efficient EEV release was observed in spite of the fact that the period of greatest glycoprotein synthesis was 8 to 12 h postinfection. The presence of 2-dg resulted in an incompletely glycosylated 89,000-molecular-weight glycoprotein, as indicated by a reduction in the apparent glycoprotein molecular weight. The morphological event affected by the inhibitors was the acquisition by INV of a double-membrane structure from the Golgi apparatus. This morphological intermediate is necessary for release of EEV.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7077747      PMCID: PMC256767     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Inhibition of the multiplication of enveloped RNA-viruses by glucosamine and 2-deoxy-D-glucose.

Authors:  G Kaluza; C Scholtissek; R Rott
Journal:  J Gen Virol       Date:  1972-03       Impact factor: 3.891

2.  An antigenic difference between intracellular and extracellular rabbitpox virus.

Authors:  G Appleyard; A J Hapel; E A Boulter
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

3.  Protection against poxviruses.

Authors:  E A Boulter
Journal:  Proc R Soc Med       Date:  1969-03-03

4.  Effects of 2-deoxy-D-glucose on herpes simplex virus replication.

Authors:  R J Courtney; S M Steiner; M Benyesh-Melnick
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus.

Authors:  G S Turner; E J Squires
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

6.  Glycoprotein synthesis in cells infected with vaccinia virus. II. A glycoprotein component of the virion.

Authors:  C F Garon; B Moss
Journal:  Virology       Date:  1971-11       Impact factor: 3.616

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Glycopeptides of vaccinia virus. I. Preliminary characterization and hexosamine content.

Authors:  J A Holowczak
Journal:  Virology       Date:  1970-09       Impact factor: 3.616

9.  Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.

Authors:  Y Ichihashi; S Matsumoto; S Dales
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

10.  Inhibition of release of vaccinia virus by N1-isonicotinoly-N2-3-methyl-4-chlorobenzoylhydrazine.

Authors:  N Kato; H J Eggers; H Rolly
Journal:  J Exp Med       Date:  1969-04-01       Impact factor: 14.307

View more
  9 in total

1.  A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release.

Authors:  C Schmutz; L G Payne; J Gubser; R Wittek
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.

Authors:  S A Duncan; G L Smith
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 3.  Viral glycoprotein metabolism as a target for antiviral substances.

Authors:  H D Klenk; R T Schwarz
Journal:  Antiviral Res       Date:  1982-09       Impact factor: 5.970

4.  A study of the glycoproteins of Autographa californica nuclear polyhedrosis virus (AcNPV).

Authors:  B Stiles; H A Wood
Journal:  Virology       Date:  1983-11       Impact factor: 3.616

5.  Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.

Authors:  G Hiller; K Weber
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

6.  The effect of cytochalasin D and monensin on enveloped vaccinia virus release.

Authors:  L G Payne; K Kristensson
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

Review 7.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

Review 8.  Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections.

Authors:  Brianna J Stubbs; Andrew P Koutnik; Emily L Goldberg; Vaibhav Upadhyay; Peter J Turnbaugh; Eric Verdin; John C Newman
Journal:  Med (N Y)       Date:  2020-07-15

9.  Effect of tunicamycin and monensin on biosynthesis, transport, and maturation of bovine herpesvirus type-1 glycoproteins.

Authors:  S van Drunen Littel-van den Hurk; L A Babiuk
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.